EGFR Pathway Expression Persists in Recurrent Glioblastoma Independent of Amplification Status
Cancers · 21.01.2023 · 15 (3) · 670
DOI: 10.3390/cancers15030670 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 21.01.2023. Verfasst von Andrew Dhawan und 4 weiteren Autor:innen. Beteiligte Einrichtung: Neurological Institute, Cleveland Clinic, Cleveland, OH 44195, USA. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Glioblastoma mortality is driven by tumour progression or recurrence despite administering a therapeutic arsenal consisting of surgical resection, radiation, and alkylating chemotherapy. The genetic changes underlying tumour progression and chemotherapy resistance are poorly understood.
Methods
In this study, we sought to define the relationship between EGFR amplification status, EGFR mRNA expression, and EGFR pathway activity. We compared RNA-sequencing data from matched primary and recurrent tumour samples (n = 40 patients, 20 with EGFR amplification).
Results
In the setting of glioblastoma recurrence, the EGFR pathway was overexpressed regardless of EGFR-amplification status, suggesting a common genomic endpoint in recurrent glioblastoma, although EGFR amplification did associate with higher EGFR mRNA expression. Three of forty patients in the study cohort had EGFR-amplified tumours and received targeted EGFR therapy. Their molecular subtypes and clinical outcomes did not significantly differ from patients who received conventional chemotherapy.
Conclusion
Our findings suggest that while the EGFR amplification may confer a unique molecular profile in primary glioblastoma, pathway analysis reveals upregulation of the EGFR pathway in recurrence, regardless of amplification status. As such, the EGFR pathway may be a key mediator of glioblastoma progression.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Neurological Institute, Cleveland Clinic, Cleveland, OH 44195, USA.
- Faculty of Pharmacy, Laval University, Quebec City, QC G1V 0A6, Canada.
- Department of Mathematics & Computer Science, University of Quebec at Trois-Rivières, Trois-Rivières, QC G8Z 4M3, Canada.
- Quebec Heart & Lung Institute Research Center, Quebec City, QC G1V 4G5, Canada.
- Department of Anatomic Pathology, Cleveland Clinic, Cleveland, OH 44195, USA.
- Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA.
ORCID-Profile: Andrew Dhawan
Zitieren
APA
Dhawan, A., Manem, V. S. K., Yeaney, G., Lathia, J. D., & Ahluwalia, M. S. (2023). EGFR Pathway Expression Persists in Recurrent Glioblastoma Independent of Amplification Status. Cancers, 15(3), 670. https://doi.org/10.3390/cancers15030670
Vancouver
Dhawan A, Manem VSK, Yeaney G, Lathia JD, Ahluwalia MS. EGFR Pathway Expression Persists in Recurrent Glioblastoma Independent of Amplification Status. Cancers. 2023;15(3):670. doi:10.3390/cancers15030670
BibTeX
@article{Dhawan2023,
author = {Dhawan, Andrew and Manem, Venkata S K and Yeaney, Gabrielle and Lathia, Justin D and Ahluwalia, Manmeet S},
title = {EGFR Pathway Expression Persists in Recurrent Glioblastoma Independent of Amplification Status},
journal = {Cancers},
year = {2023},
volume = {15},
number = {3},
pages = {670},
doi = {10.3390/cancers15030670}
}
EUVIMED